Generali Investments CEE investicni spolecnost a.s. Sells 542 Shares of Eli Lilly and Company (NYSE:LLY)

Generali Investments CEE investicni spolecnost a.s. cut its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,448 shares of the company's stock after selling 542 shares during the period. Eli Lilly and Company accounts for approximately 0.8% of Generali Investments CEE investicni spolecnost a.s.'s portfolio, making the stock its 23rd largest position. Generali Investments CEE investicni spolecnost a.s.'s holdings in Eli Lilly and Company were worth $8,629,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Olde Wealth Management LLC purchased a new position in Eli Lilly and Company during the 1st quarter valued at about $154,000. Truist Financial Corp lifted its holdings in shares of Eli Lilly and Company by 1.4% during the first quarter. Truist Financial Corp now owns 372,003 shares of the company's stock valued at $307,241,000 after purchasing an additional 5,217 shares during the last quarter. Capital Investment Advisory Services LLC boosted its position in shares of Eli Lilly and Company by 4.9% in the 1st quarter. Capital Investment Advisory Services LLC now owns 8,084 shares of the company's stock worth $6,677,000 after purchasing an additional 377 shares in the last quarter. Morris Financial Concepts Inc. increased its position in Eli Lilly and Company by 34.0% during the 1st quarter. Morris Financial Concepts Inc. now owns 2,195 shares of the company's stock valued at $1,813,000 after buying an additional 557 shares in the last quarter. Finally, Impax Asset Management Group plc raised its stake in Eli Lilly and Company by 31.9% during the first quarter. Impax Asset Management Group plc now owns 61,438 shares of the company's stock valued at $50,742,000 after buying an additional 14,876 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded down $7.85 during trading on Monday, hitting $772.82. The company had a trading volume of 2,575,478 shares, compared to its average volume of 3,663,620. The stock has a 50 day simple moving average of $773.61 and a 200 day simple moving average of $800.26. The firm has a market capitalization of $732.43 billion, a P/E ratio of 62.88, a price-to-earnings-growth ratio of 1.14 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. Eli Lilly and Company's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.58 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is presently 48.82%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on LLY shares. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. UBS Group dropped their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Finally, Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.